ArticleEuropean journal of nuclear medicine and molecular imaging2026
Prognostic role of pretreatment [
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose[18F]-fluorodesoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) is used for diagnosis and staging of adrenocortical cancer (ACC), its prognostic role needs to be explored. This study aimed to investigate the prognostic role of pre-EDP-M [18F]FDG PET/CT parameters in ACC patients treated with first line chemotherapy (ChT) in term of progression free survival (PFS) and overall survival (OS).
methodthis retrospective, monocentric study included metastatic ACC patients treated with EDP-M after [18F]FDG PET/CT staging. Clinico-pathological features and PET/CT semiquantitative parameters such as standardized uptake value (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG), SUVmax/liver ratio (SL) and SUVmax/blood-pool ratio (SBP) were collected.
resultsforty-one ACC patients were included. Median PFS was 9.3 months and median OS was 14.3 months. PET/CT parameters did not correlate with the response to ChT, while they were affordable prognosticators. Lower MTV (HR 0.36, CI: 0.17–0.74; p < 0.01), lower TLG (HR 0.31, CI: 0.15–0.64; p < 0.01), lower tumour burden (HR 0.45, CI: 0.23–0.94; p = 0.03), attained the statistical significance in univariable analysis in terms of longer PFS, lower TLG (HR 0.33, CI: 0.15–0.71; p < 0.01) confirmed its independent role in multivariable analysis. At univariable analysis lower MTV (HR 0.36, CI: 0.16–0.82; p = 0.01) correlated with longer OS. Lower TLG confirmed its role in the multivariate analysis (HR 0.28, CI 0.11–0.69; p < 0.01).
conclusionpretreatment TLG was reported as independent prognostic tools for ACC patients treated with EDP-M. No correlations between PET/CT parameters and response to ChT were reported.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.